>>> Early premarket gappers


Early premarket gappers

Gapping up:

DAC +13.4%, WWE +11%, AKAO +0.6%, HEAR +3%

Gapping down:

AQXP -80%, PTIE -70%, DRRX -14%, FOLD -10.3%, CNXM -9.1%, SONC -8.7%, SBLK -7.5%, CAG -6.5%, AVAV -6.2%, PF -4.5%, TUSK -2%, CGC -0.5%

>>> US Gapping up


Gapping up
In reaction to strong earnings/guidance:

  • DAC +11.7%, GIS +2%

Other news:

  • CARA +33.8% (announces 'positive' top-line data from the adaptive Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries)
  • WWE +10.1% (World Wrestling secures multi-year media rights deals with USA Network and Fox Sports; provides 2019 outlook - will host a conference call)
  • AKAO +2.4% (rebounding after -20% yesterday following FDA approval of ZEMDRI)
  • HEAR +1.3% (higher after announcing another 'significant' partnership as the official audio partner for Australian esports organization Tainted Minds)

Analyst comments:

  • MRVL +3.1% (upgraded to Buy at Duetsche Bank)
  • OKTA +2.1% (upgraded to Buy at Needham)
  • CSII +1.1% (upgraded to Buy from Underperform at BAML)
  • GE +1% (upgraded to Peer Perform at Oppenheimer)

>>> US Gapping down


Gapping down
In reaction to disappointing earnings/guidance:

  • SONC -8.2%, AVAV -6%, CAG -5.2%, CGC -3.2%

M&A news:

  • CAG -5.2% (Acquiring Pinncle Foods (PF) for $10.9 bln in cash and stock)
  • PF -3.6% (Acquired by ConAgra for $43.11 in cash plus 0.6494 shares of CAG)

Other news:

  • AQXP -80.7% (Phase 3 LEADERSHIP 301 clinical trial evaluating AQX-1125 for the treatment of interstitial cystitis/bladder pain syndrome failed to meet its primary endpoint) SMMT -76.3% (PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with DMD)
  • DRRX -19.0% (Pain Therapeutics reports the FDA Advisory Committee voted 14 to 3 against the approval of REMOXY ER for the management of pain)
  • CNXM -10.3% (CNX Midstream Partners commences offering of 5 mln common units representing limited partner interests in the Partnership by NBL Midstream -subsidiary of Noble Energy)
  • FOLD -7% (received written guidance from the CHMP Scientific Advice Working Party)
  • SBLK -7% (commences secondary public offering of 5 mln shares of common stock by selling shareholder, Oaktree Capital Management )
  • GBT -3.8% (Postive top-line data from Part A Phase 3 HOPE study of Voxelotor in Sickle Cell Disease)
  • TUSK -1.8% (announces underwritten public offering of 4 mln shares of common stock by selling shareholders), .

Analyst comments:

  • GMED -2.5% (downgraded to Underperform at BAML)
  • NUVA -2.2% (downgraded to Underperform at BAML)
  • CEQP -1.4% (downgraded to Neutral from Buy at Goldman)

>>> Official: President Trump seeks to maintain investment environment open in t

Official: President Trump seeks to maintain investment environment open in the US, to use CFIUS to respond to China technology theft - closed door conference call (in-line with recent speculation)
- President decided against the harshest measures on China investment
- Working to ensure final version of CFIUS Bill is strong and flexible enought to addressw national security concerns
- Will undertake an examination of export controls to deal with threats to US technology

White House Statement:
- If Congress fails to pass changes on CFIUS then Trump will direct the Administration to deploy new tools on a global basis